INKT (MiNK Therapeutics) EBIT per Share : $-0.40 (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics EBIT per Share?

MiNK Therapeutics's EBIT per Share for the three months ended in Sep. 2024 was $-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.40.

During the past 3 years, the average EBIT per Share Growth Rate was -9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MiNK Therapeutics's EBIT per Share or its related term are showing as below:

INKT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -9 Med: -5.4 Max: -1.8
Current: -9

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of MiNK Therapeutics was -1.80% per year. The lowest was -9.00% per year. And the median was -5.40% per year.

INKT's 3-Year EBIT Growth Rate is ranked worse than
65.14% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs INKT: -9.00

MiNK Therapeutics's EBIT for the three months ended in Sep. 2024 was $-1.89 Mil.

MiNK Therapeutics EBIT per Share Historical Data

The historical data trend for MiNK Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics EBIT per Share Chart

MiNK Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.87

-0.49

-1.09

-0.92

-0.67

MiNK Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial														-0.15	-0.16	-0.11	-0.08	-0.05

MiNK Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MiNK Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.921	/	34.360
=	-0.67

MiNK Therapeutics's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.885	/	39.534
=	-0.05

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40

MiNK Therapeutics (NAS:INKT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MiNK Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.minktherapeutics.com

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

Executives

Agenus Inc	10 percent owner	3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen	director	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin	officer: Treasurer	3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell	director, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum	director	3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni	director	3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner	director	3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius	officer: Chief Technology Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010